Stimuli Technology raises €7 million to accelerate the international expansion of Tensi+, its neurostimulation solution for overactive bladder

Paris, November 2, 2026 – Stimuli Technology, a French medtech company specializing in the treatment of overactive bladder, announces €7 million in financing, notably marked by Seventure Partners joining its shareholder base. This transaction will enable the company to accelerate its growth in France and internationally, strengthen its clinical investments, and continue developing Tensi+, its transcutaneous tibial nerve stimulation medical device.

Tensi+, a French innovation designed to improve patients' lives



Founded in 2018 by Technofounders, a French deeptech venture builder, Stimuli Technology addresses a major public health challenge: overactive bladder. This syndrome affects nearly one in six adults worldwide and more than 7 million people in France. Characterized in particular by sudden, difficult-to-control urges to urinate, the condition can significantly affect patients' quality of life.

To address this need, Stimuli Technology developed Tensi+, a non-drug, non-invasive treatment solution that enables patients to manage their treatment independently at home.

Designed and manufactured in France, Tensi+ is a Class IIa medical device CE-marked under the European Medical Device Regulation (MDR). Reimbursed by the French national health insurance system since 2021, it is now marketed in several countries, with more than 50,000 devices sold over five years.

A new phase of growth with Seventure Partners

Having reached key milestones in the clinical, regulatory and commercial development of Tensi+, Stimuli Technology now aims to accelerate its expansion.

Seventure Partners joining its shareholder base will enable the company to pursue four strategic priorities:

- **Strengthen its commercial presence in France**, its home market
- **Accelerate international development**, particularly in Europe and North America
- **Continue its clinical programs** to strengthen scientific evidence and support access to new markets
- **Invest in research and innovation** to further advance its technology

This new phase of development builds on established commercial momentum and a clear ambition: to make Tensi+ a leading solution for managing overactive bladder, in France and internationally.

"Seventure Partners joining our shareholder base marks a decisive milestone for Stimuli Technology. After several years spent developing, validating and commercializing Tensi+, we now have solid foundations from which to accelerate our growth. Our ambition is clear: to

deploy our technology on a larger scale and enable more patients to access a simple, non-invasive treatment they can use at home."

Delphine Agullo, CEO of Stimuli Technology

Committed partners supporting Stimuli Technology

For **Seventure Partners**, this transaction is an opportunity to support a French medtech company with differentiated technology, an established commercial presence and significant potential for international growth.

"We are delighted to support Stimuli Technology in this new phase of growth, driven by our strong belief in the potential of its non-invasive medical technology to address a major public health challenge. The company has an already validated solution with a strong presence, particularly in France, and our ambition is to help accelerate its international commercial rollout while expanding the solution into new indications and use cases."

Emmanuel Fiessinger, Managing Director at Seventure Partners

Technofounders, which founded Stimuli Technology in 2018, continues to support the company through this new stage of its development.

"At Technofounders, we create, finance and support companies developing scientific innovations capable of addressing the fundamental needs of our century. Stimuli Technology exemplifies the rigor of this model: over eight years, we have supported Tensi+ through the key stages of its development, from technology development to commercialization. With more than 50,000 devices sold, Tensi+ has demonstrated its ability to address a genuine healthcare need. Seventure Partners, a leading life sciences investor, joining the shareholder base reinforces Stimuli Technology's potential and marks a new milestone in its international development."

Olivier Le Blainvaux, Managing Partner at Technofounders

Stimuli Technology was advised by **Agile Capital Markets** in connection with this financing transaction and wishes to acknowledge the quality of its advice and its commitment throughout the process.

About Stimuli Technology

Founded in 2018 by the Technofounders startup studio, Stimuli Technology is a French medtech company specializing in the development and commercialization of innovative solutions for treating overactive bladder. Its Tensi+ medical device, CE-marked and classified as Class IIa, uses transcutaneous tibial nerve stimulation, a non-drug, non-invasive approach that allows patients to manage their treatment at home. Designed and manufactured in France, Tensi+ is marketed in France and internationally, with more than 50,000 devices sold since 2021. Stimuli Technology holds ISO 13485:2016 and MDSAP certifications.

For more information: https://www.tensiplus.com

About Seventure Partners

Seventure Partners is a long-term equity investor that actively supports innovative companies seeking to generate positive outcomes for people, society, sustainability and the planet.

With approximately €1 billion in net commitments under management as of June 30, 2026, Seventure is a leading European venture capital firm that has invested since 1997 in innovative, high-growth-potential companies in two main areas: (i) life sciences (biotechnology, healthcare and digital health, nutrition, foodtech, bioeconomy, blue economy (oceans and water), aquaculture, animal health, agriculture, sports and wellness), with a particular focus on microbiome-related innovations within a One Health approach, across Europe, Asia and North America; and (ii) digital technologies (fintech, retail tech, cybersecurity, etc.) in Western Europe.

Investment tickets range from €500,000 to €10 million per funding round and up to €20 million per company, across seed, venture capital, growth, IPO, growth equity and leveraged buyout stages.

In life sciences, Seventure primarily invests in traditional approaches such as biopharmaceuticals, medical devices, diagnostics, and industrial biotechnology or bioindustry, as well as beyond-the-pill approaches including digital health, preventive medicine, wellness, personalized medicine, nutrition and food, with particular interest in applications of microbiome discoveries and foodtech.

For more information: https://www.seventure.fr/

About Technofounders

Technofounders is an AMF-authorized asset management company that creates, finances and supports businesses originating from French scientific research. For more than 10 years, through its deeptech startup studio model, Technofounders has transformed scientific innovations into companies capable of meeting the fundamental needs of our century: improving healthcare, producing sustainably and strengthening industrial sovereignty. Through its TF Participations fund, it enables investors to become shareholders in scientific progress through a diversified portfolio of companies, from inception to Series A. Since its creation, Technofounders has created and supported 17 startups, invested more than €30 million and mobilized over €90 million in co-investments. Its flagship ventures include Cerbair, ION-X and Les Fermes Debout.

For more information: https://www.technofounders.com

Press contact

Laure de Martel
Marketing Manager at Stimuli Technology
l.demartel@stimuli-technology.com